A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
BeOne Medicines
Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed grade 1-3a FL or MZL
Previously treated with ≥ 1 line of systemic therapy including anti-CD20 agent. Must have a documented failure to achieve at least partial response during the most recent systemic therapy or documented progressive disease after the most recent systemic therapy
Need for systemic therapy for FL or MZL
Measurable disease by computed tomography or magnetic resonance imaging
Adequate bone marrow, liver and renal function
You may not be if
Transformation to aggressive lymphoma
Requiring ongoing need for corticosteroid treatment
Clinically significant cardiovascular disease
Prior malignancy within the past 2 years
Active fungal, bacterial, and/or viral infection that requires systemic therapy
Prior treatment with lenalidomide or drug from same class, if without response (partial or complete) or short remission duration (\< 24 months)
Clareo Health | A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
